Rita Jain - 16 Feb 2023 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
Director
Signature
/s/ Sam Martin, attorney-in-fact for Rita Jain, M.D.
Issuer symbol
CLDX
Transactions as of
16 Feb 2023
Net transactions value
$0
Form type
4
Filing time
21 Feb 2023, 15:30:32 UTC
Previous filing
05 Jan 2023
Next filing
06 Apr 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Non-Qualified Stock Option (right to buy) Award $0 +17,100 $0.000000 17,100 16 Feb 2023 Common Stock 17,100 $42.34 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
F2 One third vests on the first, second and third anniversaries of the date of grant.